Literature DB >> 30615097

Adaptive Immune Responses in Humans During Nipah Virus Acute and Convalescent Phases of Infection.

Govindakarnavar Arunkumar1, Santhosha Devadiga1, Anita K McElroy2,3, Suresh Prabhu1, Shahin Sheik1, Jazeel Abdulmajeed1, Sudandiradas Robin1, Aswathyraj Sushama1, Anup Jayaram1, Sudheesh Nittur1, Mohammed Shakir1, Keeriyatt Govindan Sajeeth Kumar4, Chandni Radhakrishnan4, Karayil Sakeena5, Jayasree Vasudevan5, Kalathil Joseph Reena5, Ragini Lohithakshan Sarita5, John D Klena2, Christina F Spiropoulou2, Kayla F Laserson2, Stuart T Nichol2.   

Abstract

BACKGROUND: Nipah virus (NiV) is 1 of 10 potential causes of imminent public health emergencies of international concern. We investigated the NiV outbreak that occurred in May 2018 in Kerala, India. Here we describe the longitudinal characteristics of cell-mediated and humoral immune responses to NiV infection during the acute and convalescent phases in 2 human survivors.
METHODS: Serial blood samples were obtained from the only 2 survivors of the NiV outbreak in Kerala. We used flow cytometry to determine the absolute T-lymphocyte and B-lymphocyte counts and the phenotypes of both T and B cells. We also detected and quantitated the humoral immune response to NiV by virus-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) enzyme-linked immunosorbent assay.
RESULTS: Absolute numbers of T lymphocytes remained within normal limits throughout the period of illness studied in both survivors. However, a marked elevation of activated CD8 T cells was observed in both cases. More than 30% of total CD8 T cells expressed Ki67, indicating active proliferation. Proliferating (Ki-67+) CD8 T cells expressed high levels of granzyme B and PD-1, consistent with the profile of acute effector cells. Total B-lymphocyte, activated B-cell, and plasmablast counts were also elevated in NiV survivors. These individuals developed detectable NiV-specific IgM and IgG antibodies within a week of disease onset. Clearance of NiV RNA from blood preceded the appearance of virus-specific IgG and coincided with the peak of activated CD8 T cells.
CONCLUSIONS: We describe for the first time longitudinal kinetic data on the activation status of human B- and T-cell populations during acute NiV infection. While marked CD8 T-cell activation was observed with effector characteristics, activated CD4 T cells were less prominent.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  NVD; Nipah virus; immune response

Year:  2019        PMID: 30615097     DOI: 10.1093/cid/ciz010

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

Review 1.  The Immunobiology of Nipah Virus.

Authors:  Yvonne Jing Mei Liew; Puteri Ainaa S Ibrahim; Hui Ming Ong; Chee Ning Chong; Chong Tin Tan; Jie Ping Schee; Raúl Gómez Román; Neil George Cherian; Won Fen Wong; Li-Yen Chang
Journal:  Microorganisms       Date:  2022-06-06

Review 2.  Henipavirus Immune Evasion and Pathogenesis Mechanisms: Lessons Learnt from Natural Infection and Animal Models.

Authors:  Philip Lawrence; Beatriz Escudero-Pérez
Journal:  Viruses       Date:  2022-04-29       Impact factor: 5.818

3.  Human Paramyxovirus Infections Induce T Cells That Cross-React with Zoonotic Henipaviruses.

Authors:  Rory D de Vries; Alwin de Jong; R Joyce Verburgh; Lucie Sauerhering; Gijsbert P van Nierop; Robert S van Binnendijk; Albert D M E Osterhaus; Andrea Maisner; Marion P G Koopmans; Rik L de Swart
Journal:  mBio       Date:  2020-07-07       Impact factor: 7.867

4.  Dynamics of human B and T cell adaptive immune responses to Kyasanur Forest disease virus infection.

Authors:  Santhosha Devadiga; Anita K McElroy; Suresha G Prabhu; Govindakarnavar Arunkumar
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

5.  Peripheral immune response in the African green monkey model following Nipah-Malaysia virus exposure by intermediate-size particle aerosol.

Authors:  Abigail Lara; Yu Cong; Peter B Jahrling; Mark Mednikov; Elena Postnikova; Shuiqing Yu; Vincent Munster; Michael R Holbrook
Journal:  PLoS Negl Trop Dis       Date:  2019-06-05

6.  A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice.

Authors:  Georgia Kalodimou; Svenja Veit; Sylvia Jany; Ulrich Kalinke; Christopher C Broder; Gerd Sutter; Asisa Volz
Journal:  Viruses       Date:  2019-12-24       Impact factor: 5.048

7.  Henipaviruses: an expanding global public health concern?

Authors:  Jorge Quarleri; Verónica Galvan; M Victoria Delpino
Journal:  Geroscience       Date:  2022-10-11       Impact factor: 7.581

8.  Vaccines to Emerging Viruses: Nipah and Hendra.

Authors:  Moushimi Amaya; Christopher C Broder
Journal:  Annu Rev Virol       Date:  2020-09-29       Impact factor: 10.431

Review 9.  Recent advances in the understanding of Nipah virus immunopathogenesis and anti-viral approaches.

Authors:  Rodolphe Pelissier; Mathieu Iampietro; Branka Horvat
Journal:  F1000Res       Date:  2019-10-16

10.  Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine.

Authors:  Rebecca J Loomis; Anthony T DiPiazza; Samantha Falcone; Tracy J Ruckwardt; Kaitlyn M Morabito; Olubukola M Abiona; Lauren A Chang; Ria T Caringal; Vladimir Presnyak; Elisabeth Narayanan; Yaroslav Tsybovsky; Deepika Nair; Geoffrey B Hutchinson; Guillaume B E Stewart-Jones; Lisa A Kueltzo; Sunny Himansu; John R Mascola; Andrea Carfi; Barney S Graham
Journal:  Front Immunol       Date:  2021-12-08       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.